Linerixibat is a Small Molecule owned by GSK, and is involved in 15 clinical trials, of which 11 were completed, 3 are ongoing, and 1 is planned.

linerixibat acts as ileal bile acid transport (IBAT) inhibitor. Increased intestinal bile acid absorption and expansion of the bile acid pool has been implicated in the hypercholesterolemia and diabetes mellitus. It interferes with the active transport system whereby bile acids are moved across the gut wall on their way back to the liver. Inhibition of IBAT causes the liver to convert cholesterol into bile acids, reducing its hepatocellular cholesterol concentration, triggering upregulation of LDL receptors and reducing serum LDL levels.

The revenue for Linerixibat is expected to reach a total of $609m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Linerixibat NPV Report.

Linerixibat is originated and owned by GSK.

Linerixibat Overview

Linerixibat is under development for the treatment of cholestatic pruritus in patients with primary biliary cirrhosis (PBC). The drug candidate is administered as an orally as a tablet or as a solution. GSK-2330672 is a small molecule, which acts by targeting an ileal bile acid transporter. It is a new molecular entity. It was also under development for the treatment of type 2 diabetes.

GSK Overview

GSK is a healthcare company that focuses on developing, manufacturing and commercializing pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterials, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.

The company reported revenues of (British Pounds) GBP34,114 million for the fiscal year ended December 2021 (FY2021), an increase of 0% over FY2020. In FY2021, the company’s operating margin was 18.1%, compared to an operating margin of 22.8% in FY2020. In FY2021, the company recorded a net margin of 12.9%, compared to a net margin of 16.9% in FY2020. The company reported revenues of GBP7,829 million for the third quarter ended September 2022, an increase of 13% over the previous quarter.

Quick View – Linerixibat

Report Segments
  • Innovator
Drug Name
  • Linerixibat
Administration Pathway
  • Oral
Therapeutic Areas
  • Dermatology
  • Metabolic Disorders
Key Companies
  • Sponsor Company: GSK
  • Originator: GSK
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.